implications for discovering control measures for apicomplexan parasites, given that they display certain plant-like physiological processes that can be targeted for selective inhibition.
The malaria parasite mtDNA turns out to be the smallest known among eukaryotes, encoding just 3 proteins and scrambled pieces of ribosomal RNA. Over the years, my colleagues and I noted significant differences in the active sites of the mitochondrial electron transport chain (mtETC) protein cytochrome b, which we showed to be the reason for the selective toxicity of certain antimalarial drugs. Selective inhibition of parasite mtETC has proven to be a fertile area for antimalarial drug discovery. Our demonstration that the parasite mtDNA is inherited from female gametes has allowed determination of directionality of mating in the progeny of parasite genetic crosses; in one cross, all progeny had the same maternal parent, suggesting unidirectional incompatibility, the significance of which remains to be explored. We also found that malarial mtDNA is highly conserved across distant parasite isolates, which has allowed others to establish phylogenetic relationships among parasite isolates. We have carried out extensive genetic studies to understand the importance of various canonical pathways usually relegated to the mitochondrion. It seems the only essential function of the mtETC in blood stages of P. falciparum is to provide oxidized ubiquinone, serving mitochondrially located pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHOD). Right now, there are clinical trials underway with parasite DHOD inhibitors being developed as antimalarial drugs. We also found that most of the tricarboxylic acid cycle enzymes are dispensable in the blood stages of P. falciparum but become critical in insect stages. Overall, the picture of the parasite mitochondrion that emerges from all the studies thus far is that of an organelle with minimal but very essential functions for parasite survival and thus a very attractive target for antimalarial drugs.
My metamorphosis into a parasitologist has been immensely rewarding. I have derived great pleasure in knowing and working with outstanding colleagues all over the world. Recently, we discovered yet another pathway in malaria parasites that is inhibited by a large number of chemical classes with antimalarial properties, some of which are undergoing clinical trials. I remain very excited to explore the intricacies of this pathway. It would be wonderful to see one of these compounds deployed as an antimalarial drug that could potentially save millions of lives. I have never regretted canceling my Journal of Virology subscription.
